Biotechnology firm CellPoint of Englewood, CO, is collaborating with Philips Medical Systems to optimize an advanced molecular imaging agent for use on the Dutch company's Skylight gantryless gamma camera. The joint goal is to develop a cost-effective,
Biotechnology firm CellPoint of Englewood, CO, is collaborating with Philips Medical Systems to optimize an advanced molecular imaging agent for use on the Dutch company's Skylight gantryless gamma camera. The joint goal is to develop a cost-effective, readily accessible technology for diagnosing cancer and prescreening patients for therapy. The focus of the agreement is CellPoint's ethylenedicysteine (EC) drug conjugate, which chemically links tissue-specific ligands (such as hormones, proteins, peptides, and glucose analogues) or pharmaceutical compounds to radioisotopes. The combined agents are being designed for cancer diagnosis and treatment. The two companies will collaborate on CellPoint's first molecular imaging agent, Tc-99m-EC-deoxyglucose, which allows deoxyglucose to be labeled with technetium-99m. Such unions with Tc-99m have been difficult to forge because the radioisotope is resistant to currently available coupling compounds. EC promises to overcome that difficulty. Philips and CellPoint will share clinical trial costs to develop this technology, according to executives at the companies. Phase I clinical studies began April 2003 at the University of Texas M. D. Anderson Cancer Center in Houston. Philips plans to review trial data and determine whether adjustments in acquisition protocols or postprocessing are needed to improve image quality.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.